| 1. |
|
Sows greater ability to replicate in cancer cells, which are high in telomerase activity;
|
| 2. |
|
Destroys cancer cells through explosive replication within the tumor cells;
|
3. |
|
Unlike gene therapy, Telomelysin® does not transfer genes to cells;
|
| 4. |
|
Working specifically on cancer cells, Telomelysin® is expected to reduce systemic adverse effects;
|
| 5. |
|
Expected to be effective against remote metastatic tumors;
|
6. |
|
Expected to significantly improve patient QOL (quality of life)
|
